U.S. Markets closed

Osiris Therapeutics, Inc. (OSIR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.84+0.04 (+0.59%)
At close: 3:55PM EDT
People also watch
  • New publication supports the science for Grafix

    Understanding the Impact of Preservation Methods on the Integrity and Functionality of Placental Allografts
    Annals of Plastic Surgery: August 2017 - Volume 79 - Issue 2 - p 203–213

    Results: The structure and thickness of fresh hPM were retained in vCHAM but were compromised in dHACM. Similar to fresh hPM, vCHAM contained viable cells, whereas dHACM did not. Cells in vCHAM remained viable after 4 and 7 days in culture and in an in vitro chronic wound environment and after 4 and 8 days in vivo after application to a mouse chronic wound. Staining for bromodeoxyuridine and Ki-67 did not reveal proliferative cells within fresh hPM and vCHAM. However, isolated cells proliferated in culture. Viable cryopreserved human amniotic membrane increased platelet-derived growth factor BB, hepatocyte growth factor, and epidermal growth factor levels over time and responded to chronic wound stimuli in vitro by significantly increasing levels of vascular endothelial growth factor and prostaglandin E2. Dehydrated human amnion/chorion membrane showed no significant accumulation of growth factors and did not respond to chronic wound stimuli.

    Conclusions: These results indicate that vCHAM retains intact, native matrix, and viable, active cells and responds to chronic wound stimuli in vitro. The inclusion of multiple layers of hPM does not compensate for structural degradation and loss of viability caused by dehydration as evidenced by a lack of functional response by dHACM. The clinical significance of these results remains to be answered.
  • Babykahn and Techfan20

    I appreciate you sharing your information. Your post are most productive and informative . I reprint the 8k about Lode's resignation. Seems mutual, he got his options extended, and there is the standard noncompeting clause. Look forward to further info!
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    (e) Separation and Release Agreement with Lode Debrabandere, Ph.D.

    Osiris Therapeutics, Inc. (the “ Company ”) is filing this Current Report on Form 8-K/A to amend its Current Report on Form 8-K filed on February 3, 2016 (the “ Original Filing ”) that reported, among other things, the resignation of Lode Debrabandere, Ph.D., as the Company’s Chief Executive Officer, President, and a director. This Form 8-K/A amends and supplements the Original Filing to disclose the terms of Dr. Debrabandere’s resignation as required pursuant to Item 5.02 on Form 8-K.

    On February 22, 2016, the Company and Dr. Debrabandere entered into a Separation and Release Agreement (the “Agreement ”), that provides for, among other terms, (i) a separation date of February 16, 2016 (the “ Separation Date ”), (ii) a consulting period from the Separation Date through May 31, 2016 for Dr. Debrabandere to assist with the smooth and orderly transition of his former responsibilities, (iii) reimbursement for the extension of certain employee benefits during the consulting period if elected by Dr. Debrabandere, (iv) extension of the expiration date to December 31, 2017 for up to 36,250 previously granted and exercisable stock options at their existing exercise prices, (v) non-disparagement, (vi) compliance with certain post-employment restrictions in Dr. Debrabandere’s Employment Agreement, including with respect to confidentiality, inventions and patents, non-competition and non-solicitation, and (vii) a release of claims by Dr. Debrabandere.
  • 2017 Veteran Administration (VA) sales of Cartiform and BIO4:

    Cartiform Jan 2017 $43,472...BIO4 $8,218.
    Cartiform Feb 2017 $51,229...BIO4 $8,757.
    Cartiform Mar 2017 $96,896...BIO4 $4,725.
    Cartiform Apr 2017 $72,669...BIO4 $8,664.
    Cartiform May 2017 $17,000...BIO4 $0.
    Cartiform Jun 2017 $0.............BIO4 $91,598.
    Cartiform Jul 2017 $14,750...BIO4 $ 0.
    2017 Total Cartiform $296,016...BIO4 $121,362.
  • Aziyo Biologics, Inc

    check out the leadership page...

    Then check out the products page...

    Then check out the corporate headquarters location...
  • Osiris had $27M in cash and no debt as of Dec 31, 2016 per this filing

    and $10M was received last week from Mesoblast (see www.mesoblast.com, Under Latest News Click "10 July 2017 Cleansing notice and Appendix 3B >")

    and if 2017 operations are near breakeven,

    then there could be $1 per share in cash. and no debt.

    Not bad for a firm with $3.18 to $3.30 of revenue per share in 2016. ($110 to $114 )/34.5 million shares

    Osiris Therapeutics - Current Report
  • New Venturetec doesn't post much information either. Must be something with the management.
  • Osiris is searching for a Scientist - Process Development Lead

    Develop and optimize cell culture processes for the production of recombinant antibodies and other recombinant proteins.


    Scientist - Process Development Lead
    PRIMARY PURPOSE OF THIS POSITION: Develop and optimize cell culture processes for the production of recombinant antibodies and other recombinant proteins. RESPONSIBILITIES: The specific duties and responsibiliti
  • Osiris is searching for an Associate Regional Sales Specialist in the Raleigh-Durham, North Carolina Area


    Associate Regional Sales Specialist
    We are looking for a go getter, able to navigate the medical system and build relationships in order to heal patients. The Associate Sales Specialist is a field based position where the Specialist acts as an ambassador for Osiris Therapeutics
  • OSIR lawyers updated the judge in the Shareholder lawsuit. It looks like target date for restatement is now by the end of September.

    "The prior Joint Status Report stated that the Company had the objective of filing restated
    2015 financial statements and original 2016 financial statements this summer. Osiris has made
    substantial progress in its restatement efforts and, although the pace of this process is controlled
    largely by Osiris’s independent public accountants, the Company is making every effort to
    complete its 2015 and 2016 financial statements by the end of September 2017."
  • Next step, canceled contract with styker and artrex for bio4 and cartiform.
    Next step, sale of grafix and nothing comes to us.
    Next step, all our technology goes to aziyo.
    Final of the story: Peter takes the money, we stay with nothing in his hand, and ozark will say it's a good thing ....
    Ps: I stay longs I want to see how stupid I am
  • Triple digits yet Ozark580? It's approaching 3 years...you loudmouth ignorant blowhard.
  • Grafix DFU trial now completed. Expect results to be posted soon #NCT02675855
  • publishing the figures and nasdaq listing will have major effects on our stock price.2015 and 2016 sales and cash 2016 are known. so q1 and q2 will be the news. any major change in sales volumes will have major effect on the stock price. once figures are out, insiders are free to invest and risk arbitrage will start to buy in. i expect a jump to about $ 15 because of few shares available. return to nasdaq will bring us up to about $ 25 (6xsales) but we need good current sales figures. we may jump much higher for lack of available shares. will be interesting to see what happens !
  • getting back to normal valuation should be a top priority. a good opportunity to bolster our cash position by making a secondary issue was missed, when we were trading above $ 20. If our grafix work horse was not going so well, we could have gotten in serious troubles.lots of cash is needed to quickly develop our huge markets (heavy dfu 1 bio $). to get out of this situation we need well informed investors, a fair stock valuation and a growth oriented financial plan.
  • its everybodys guess when financial datas will be published. As a non reporting company, they seem to be in no hurry. they did not care to publish a 1st quarter sales estimate. the starting date july 10 th for our new ceo points to some urgency. 5 weeks should be enough to get up to speed. if they do not publish by aug. 15, they would miss normal q 2 reporting deadline.if an agm would be scheduled for early september (after holidays ) that would leave 30 day announcement time pointing to early august as well. confirming all those directors is much needed. after all those mistakes made by bdo and management confidance has to be restored.
  • This is the most recent info on Prestige that I can find...co authored by Osiris CSO Ms. Danilkovitch...

  • we are having now a much more qualified and independent board. internal controls were neglected before. i was very dissapointed to hear that accounting was part of the sales department. much to long payment terms were not corrected. a dramatic hire and fire cylce took place. this may explain the long audit time. ey have to make sure everything is ok now. lets hope new management can turn now to the tremendes opportunities with our fantastic products.
  • It looks like Academy Medical recently signed a $1,758,612 contract with the VA for future shipments of Osiris Grafix and Stravix. Contract # VA11916D0043 and Osiris has already shipped 2% of the contract. Interesting in that two of these shipments were for "shoulder implants". Apparently the use of Grafix in surgical procedures is being utilized.
  • Osiris Grafix is keeping pace with Epifix in Veteran Administration (VA) sales and probably gaining ground on them. Thus far in their fiscal year 2017, Epifix has done 226 transactions for Epifix and Grafix has done 113...exactly 50% of their rate. June sales for Epifix were $82,404 and Grafix was $77,024.

    Grafix sales are doing quite well with et
  • Tell us again Ozark580 how “…MDXG’s growth is slowing dramatically”

    Second Quarter 2017 Revenue Highlights:
    • Q2 2017 Revenue of $76.4 Million exceeds MiMedx guidance range of $73.5 to $75.0 Million
    • Q2 2017 Revenue grew 33% over Q1 2016 revenue
    • First Six Months of 2017 Revenue grew 35% over First Six Months of 2016

    The Company recorded record revenue for the 2017 second quarter of $76.4 million, a $19.1 million or 33% increase over 2017 second quarter revenue of $57.3 million. Revenue for the six months ended June 30, 2017 was $149 million, a $38.3 million or 35% increase over revenue for the six months ended June 30, 2016 of $110.7 million.

    The “company” being mentioned here is, of course, the market leader…MiMedx